title: Induction chemotherapy with cisplatin, vinorelbine, and mitomycin-C followed by surgery for patients with pathologic N2 non-small-cell lung cancer.
abstract: OBJECTIVE
  The treatment strategy for patients with non-small-cell lung cancer (NSCLC) involving ipsilateral mediastinal lymph nodes is still controversial. We performed a phase II feasibility study of induction chemotherapy followed by surgery for patients with pathologic N2 NSCLC.
  
  
  METHODS
  Patients with mediastinoscopy- positive stage IIIA N2 NSCLC received 2 cycles of cisplatin 80 mg/m2, vinorelbine 25 mg/m2, and mitomycin-C 8 mg/m2. Patients without progressive disease underwent thoracotomy and lobectomy with lymph node dissections 2-4 weeks later.
  
  
  RESULTS
  From January 2000 to July 2004, 24 eligible patients (15 men, 9 women) were enrolled. Induction chemotherapy was completed as planned in 23 patients (95.8%). Hematological toxicity was the primary grade 3/4 toxicity. Twelve (50%) patients achieved a partial response. Twenty-three patients underwent surgical resection, and complete resection was achieved in 22 patients (95.7%). There were no surgery-related deaths. Pathologic complete response in metastatic lymph nodes was achieved in 5 patients. With a median follow-up of 5.4 years (range, 2.88-7.7 years), the estimated 5-year survival was 51.8% (95% CI, 41.3-62.3) and progression-free survival was 46.6% (95% CI, 36-57.2).
  
  
  CONCLUSIONS
  Induction chemotherapy followed by surgery for patients with pathologic N2 NSCLC was feasible and associated with high response to lymph node metastasis and good survival.
authors.affiliation: Department of Chest Surgery, Oita Prefectural Hospital, Oita, Japan. akamine@oitakenbyo.jp
authors.forename: Shinji
authors.initials: S
authors.lastname: Akamine
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Oka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Soda
authors.forename: Hideki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Fukuda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Minami
authors.forename: Seiji
authors.initials: S
authors.lastname: Nagashima
authors.forename: Kazuto
authors.initials: K
authors.lastname: Ashizawa
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Goya
authors.forename: Mikio
authors.initials: M
authors.lastname: Oka
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tagawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nagayasu
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D010349:Patient Compliance; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D016685:Mitomycin; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine